Short answer
Esperion Therapeutics, Inc. (ESPR) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $87M (up 69.1% year over year) with net income of −$31M.
Q3 2025 key financials · XBRL
- Revenue
- $87M
- +69.1% YoY · +6.0% QoQ
- Net income
- −$31M
- −6.1% YoY · −146.2% QoQ
- Operating margin
- -11.4%
- EPS (diluted)
- −$0.16
- +0.0% YoY · −166.7% QoQ
Source: XBRL data from the Esperion Therapeutics, Inc. (ESPR) Q3 2025 10-Q on SEC EDGAR. USD.
Esperion Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $87.3M vs $51.6M, up $35.7M YoY
- Product sales $40.7M vs $31.1M; collaboration revenue $46.7M vs $20.5M
- Operating loss $10.0M vs $16.0M; operating margin -11.4% vs -31.1% YoY
- Best performer collaboration revenue, up $26.2M; worst cost of goods sold, up $24.0M
- Net loss $31.3M vs $29.5M; interest expense $22.1M vs $15.1M driven by Loan interest
Risk Factors
- Newly added healthcare-policy risk: Executive Orders 14273 and 14297 target drug-price negotiation and most-favored-nation pricing
- Most materially updated regulatory risk: September 2025 proposed 100% tariff on brand-name or patented drugs, currently on hold
- Supply-chain compliance risk: proposed BIOSECURE-related restrictions could limit Chinese biotechnology suppliers and collaborators
- Financial risk: macroeconomic deterioration could weaken demand and restrict access to additional capital on acceptable terms
- Tax-law risk: OBBBA Act changes research-and-development capitalization, interest deductions, and fixed-asset depreciation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Esperion Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.